

# Generalizable survival analysis of randomized controlled trials with observational studies

Dasom Lee<sup>1</sup>, Shu Yang<sup>1,\*</sup>, Xiaofei Wang<sup>2</sup>

<sup>1</sup>Department of Statistics, North Carolina State University, Raleigh, NC, U.S.A.

<sup>2</sup>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, U.S.A.

\**email*: syang24@ncsu.edu

## Abstract

In the presence of heterogeneity between the randomized controlled trial (RCT) participants and the target population, evaluating the treatment effect solely based on the RCT often leads to biased quantification of the real-world treatment effect. To address the problem of lack of generalizability for the treatment effect estimated by the RCT sample, we leverage observational studies with large samples that are representative of the target population. This paper concerns evaluating treatment effects on survival outcomes for a target population and considers a broad class of estimands that are functionals of treatment-specific survival functions, including differences in survival probability and restricted mean survival times. Motivated by two intuitive but distinct approaches, i.e., imputation based on survival outcome regression and weighting based on inverse probability of sampling, censoring, and treatment assignment, we propose a semiparametric estimator through the guidance of the efficient influence function. The proposed estimator is doubly robust in the sense that it is consistent for the target population estimands if either the survival model or the weighting model is correctly specified, and is locally efficient when both are correct. Simulation studies confirm the theoretical properties of the proposed estimator and show it outperforms competitors. We apply the proposed method to estimate the effect of adjuvant chemotherapy on survival in patients with early-stage resected non-small lung cancer.

**Keywords:** Causal inference, Data integration, Generalizability, Survival analysis, Semiparametric efficiency.

# 1 Introduction

In clinical trials or biomedical studies, time-to-event or survival endpoints, such as the time from treatment initiation to death, have been commonly used to evaluate the treatment effect. When estimating treatment effect, randomized controlled trials (RCTs) are regarded as the gold standard since randomization reduces the effect of confounding variables. However, RCTs often suffer from a lack of generalizability or external validity. Specifically, due to restrictive inclusion and exclusion criteria for enrollment or additional concerns from patients and physicians, RCTs often don't recruit enough participants that represent the real-world patient population, resulting in the covariate distribution of the RCT sample being different from that of the target real-world population. In the presence of such heterogeneity, evaluating the treatment effect based solely on the RCT sample leads to biased quantification of the real-world treatment effect. As a complement of the RCT sample, observational studies have been widely used in comparative effectiveness research, as large samples that are representative of the target population can be studied at a relatively low cost.

Several recent works have proposed integrative methods to generalize findings from the RCT to the target population by leveraging observational studies (Cole and Stuart, 2010; Tipton, 2013; Hartman et al., 2015; Dahabreh et al., 2019; Lee et al., 2021). Most existing methods focus on directly modeling the probability of participating in the trial, i.e., the sampling score which is analogous to the treatment propensity score. A widely used approach involves inverse probability of sampling weighting (IPSW; Cole and Stuart, 2010; Stuart et al., 2011), which can be used to estimate weight-adjusted survival curves (Cole and Hernán, 2004; Pan and Schaubel, 2008). However, these IPSW-based estimators are unstable under extreme sampling scores. Alternatively, Lee et al. (2021) proposed calibration weighting that enforces covariate balance between the RCT and observational study without explicitly modeling the sampling score. Recently, Colnet et al. (2020) provided a comprehensive review of various novel methods combining complementary features of RCTs and observational studies. However, most of these methods focus on continuous and bi-

nary outcomes, and generalization of the findings from RCTs for survival outcomes to the target population is less actively studied.

In this paper, we consider a broad class of estimands defined as a functional of treatment-specific survival functions, including differences in survival probability at landmark times and restricted mean survival time (RMST). Various estimators can be constructed to adjust for the selection bias of the RCT sample. One approach relies on fitting conditional survival outcome models and then averaging over the covariate distribution of the observational sample, similar to Chen and Tsiatis (2001). Another common approach is to use weighting (Cole and Hernán, 2004; Wei and Schaubel, 2008) to adjust for the imbalance between the RCT sample and the observational sample. Instead of direct modeling of sampling score as in IPSW, one can consider the more stable approach that calibrates covariate distributions between the RCT and the observational sample (Lee et al., 2021). Motivated by these two intuitive but distinct approaches, we propose improved estimators for survival outcomes under the guidance of the efficient influence function (EIF), which involve survival outcome regression and weighting based on inverse probability of treatment, censoring, and sampling, simultaneously. The proposed estimator is doubly robust in the sense that it is consistent for the target population estimand if either the survival model or the weighting model is correctly specified, and is locally efficient when both are correct.

The remainder of the paper is organized as follows. In Section 2, we formalize the basic causal inference framework for survival outcomes. In Section 3, we introduce two direct estimators based on identification formulas, and in Section 4, we propose improved estimators and describe the corresponding asymptotic properties. The finite sample performance of the proposed estimators is assessed via simulation studies in Section 5. Applying the proposed estimators, we analyze the effect of adjuvant chemotherapy on the survival of lung cancer patients with data from an RCT and an observational study in Section 6. Section 7 presents the discussion and concluding remarks. All proofs are provided in the Appendix.

## 2 Notation and Assumptions

Suppose we are interested in comparing the effectiveness of two treatments. Let  $A$  be the binary treatment assignment,  $A \in \{0, 1\}$ . Following the potential outcomes framework (Rubin, 1974, 1986), let  $T^a$  be the potential survival time if a subject received the treatment  $A = a$ , and  $S_a(t)$  and  $\lambda_a(t)$  be the corresponding survival and hazard functions, i.e.,  $S_a(t) = P(T^a \geq t)$  and  $\lambda_a(t) = \lim_{h \rightarrow 0} h^{-1} P(t \leq T^a \leq t + h) / P(T^a \geq t)$ . Under the proportional hazards assumption, a widely used measure to characterize the treatment effect is hazard ratio (HR), i.e.,  $\lambda_1(t) / \lambda_0(t)$  being a constant. However, the interpretation of HRs is challenging especially when the proportionality assumption is violated (Hernán, 2010; Trinquart et al., 2016).

Alternatively, we define the average treatment effect (ATE) measure  $\theta_\tau$  as a function of treatment-specific survival curves,  $\theta_\tau = \Psi_\tau(S_1(t), S_0(t))$  where  $\tau$  is a pre-specified constant. This formulation of the ATE includes a broad class of estimands that are favored in survival analysis (Yang et al., 2020). For example,  $\theta_\tau = S_1(\tau) - S_0(\tau)$  is a simple survival difference at a fixed time  $\tau$ , and  $\theta_\tau = \int_0^\tau \{S_1(t) - S_0(t)\} dt$  is the restricted mean survival time (RMST) difference up to  $\tau$ . The ratio of restricted mean time loss (RMTL) and the difference of the median survival can also be represented with the appropriate choice of  $\Psi_\tau(\cdot)$ .

Under the Stable Unit Treatment Value Assumption, the survival time  $T$  is the realization of the potential outcomes, i.e.,  $T = T^1 A + T^0 (1 - A)$ . Let  $C$  be the censoring time. In the presence of right censoring, the survival time  $T$  is not observed for all subjects; instead, we observe  $U = T \wedge C$  and  $\Delta = I(T \leq C)$  where  $\wedge$  represents the minimum of two values, and  $I(\cdot)$  is an indicator function. Let  $X$  be a  $p$ -dimensional vector of pre-treatment covariates. Also, let  $\delta$  denotes the binary indicator of RCT participation, and let  $\tilde{\delta}$  denotes the binary indicator of observational study participation. We consider a super-population framework assuming that an RCT sample of size  $n$  and an observational sample of size  $m$  are sampled from the target population. From the RCT sample, we observe  $\{U_i, \Delta_i, A_i, X_i, \delta_i = 1, \tilde{\delta}_i = 0\}$  from  $i = 1, \dots, n$  independent and identically distributed subjects.




Figure 1: Illustration of the data structure of the RCT sample and the observational study (OS) sample within the target super-population framework.

For the observational sample, it is common that only the covariates information is available, i.e.,  $\{X_i, \delta_i = 0, \tilde{\delta}_i = 1\}$  from  $i = n + 1, \dots, n + m$  independent and identically distributed subjects. The sampling mechanism and data structure are illustrated in Figure 1. We assume independence between the RCT and the observational sample, which holds if two separate studies are conducted by independent researchers, the target patient population is sufficiently large, or the patients are enrolled in two separate time periods.

Let  $S_a(t | X) = S(t | X, A = a, \delta = 1)$  be the treatment-specific conditional survival curves for  $a, \delta \in \{0, 1\}$ . Also, define the treatment propensity score  $\pi_A(X) = P(A = 1 | X, \delta = 1)$  and the sampling score  $\pi_\delta(X) = P(\delta = 1 | X)$ . In order to identify the ATE from the observed data, we make the following assumptions:

**Assumption 1 (Ignorability and positivity of trial treatment assignment)**

(i)  $\{T^0, T^1\} \perp\!\!\!\perp A \mid (X, \delta = 1)$ ; and (ii)  $0 < \pi_A(X) < 1$  with probability 1.

**Assumption 2 (Conditional survival exchangeability and positivity of trial participation)**

(i)  $S_a(t \mid X, \delta = 1) = S_a(t \mid X)$ ,  $a \in \{0, 1\}$ ; and (ii)  $\pi_\delta(X) > 0$  with probability 1.

**Assumption 3 (Noninformative censoring conditional on covariates and treatment)**

$\{T^1, T^0\} \perp\!\!\!\perp C \mid (X, A, \delta = 1)$ , which also implies  $T \perp\!\!\!\perp C \mid (X, A, \delta = 1)$ .

Assumptions 1–3 are not testable in general and their plausibility should be justified based on subject matter knowledge in practice. Assumption 1 holds in the RCT by default. Assumption 2 (i) is plausible if all information related to the trial participation and the outcome is captured in the data at hand. This assumption is weaker than the ignorability of the trial participation assumption, i.e.,  $\{T^0, T^1\} \perp\!\!\!\perp \delta \mid X$ . The relationship between Assumption 2 (i) and its stronger version is analogous to that described in Dahabreh et al. (2019) in the context of continuous and binary outcomes. Assumption 2 (ii) implies that the absence of patient characteristics that prevent from participating in the trial (Lee et al., 2021). Assumption 3 is commonly made in survival analysis (Chen and Tsiatis, 2001; Zhang and Schaubel, 2012b; Zhang et al., 2019). This assumption is weaker than the conditional independence assumption of the censoring and survival time given only on the treatment (Zhang and Schaubel, 2012a).

The covariate distribution of the RCT sample  $f(X \mid \delta = 1)$  may not be representative of that of the target population  $f(X)$  due to restrictive trial enrollment criteria, but the covariate distribution of the observational sample  $f(X \mid \tilde{\delta} = 1)$  is often representative of  $f(X)$  due to the real-world data collection mechanism. In particular, if the observational sample is a simple random sample of the target population, then  $f(X \mid \tilde{\delta} = 1) = f(X)$ . More generally, the observational sample can be selected under complex sampling designs. To accommodate such scenarios, we can define  $d$  as the known design weight for the observational sample.

**Assumption 4 (The known design weight for the observational sample)**

The observational sample design weight  $d = 1/P(\tilde{\delta} = 1 | X)$  is known.

Assumption 4 is commonly assumed in the survey sampling literature. Based on Assumption 4, the design-weighted observational sample is representative of the target population. In an observational study with simple random sampling,  $d = N/m$ , where  $N$  is the target population size.

Under the above assumptions, the ATE  $\theta_\tau$ , or  $S_a(t)$ ,  $a \in \{0, 1\}$  sufficiently, are identified based on the observed data. We consider two identification formulas. Let  $Y(t) = I(U \geq t)$ , and define the conditional censoring model  $S^C(t | X, A) = P(C > t | X, A, \delta = 1)$ . One identification formula is based on the conditional survival curves, i.e.,

$$S_a(t) = \mathbb{E} \left\{ \tilde{\delta} d S_a(t | X) \right\}, \quad S_a(t | X) = \mathbb{E} \{ I(T \geq t) | X, A = a, \delta = 1 \} \quad (1)$$

and the other identification formula is based on the inverse probability weighting (IPW) approach for the marginal survival curves, i.e.,

$$S_a(t) = \mathbb{E} \left[ \frac{\delta}{\pi_\delta(X)} \frac{I(A = a)}{\pi_A(X)^a \{1 - \pi_A(X)\}^{1-a}} \frac{Y(t)}{S^C(t | X, A)} \right], \quad (2)$$

for  $a \in \{0, 1\}$ . The two identification formulas in (1) and (2) motivate the estimators in the following section, depending on different components of the observed data likelihood.

### 3 Two Direct Estimators based on Identification Formulas

#### 3.1 Outcome Regression

Based on the identification formula (1), the treatment-specific conditional survival curve can be modeled and fitted based on the observed data, e.g., using the widely used Cox regression model for the survival outcome. A treatment-specific conditional hazard function at time  $t$  given covariate  $X_i$  is defined as

$$\lambda_{ai}(t) \equiv \lambda_a(t | X_i) = \lambda_{a0}(t) \exp(\beta_a^T X_i), \quad (3)$$

where  $\lambda_{a0}(t)$  is a treatment-specific baseline hazard function, for  $a \in \{0, 1\}, i = 1, \dots, n$ . Following standard survival analysis techniques,  $\beta_a$  can be estimated as a solution to the partial likelihood score equation, and the baseline cumulative hazard  $\Lambda_{a0}(t) \equiv \int_0^t \lambda_{a0}(u)$  can be estimated by the Breslow (1974) estimator,

$$\hat{\Lambda}_{a0}(t) = \int_0^t \frac{\sum_{i=1}^N \delta_i A_{ai} dN_i(u)}{\sum_{i=1}^N \delta_i A_{ai} \exp(\hat{\beta}_a^T X_i) Y_i(u)},$$

where  $A_{ai} = I(A_i = a)$ ,  $N_i(u) = I(U_i \leq u, \Delta_i = 1)$ , and  $Y_i(u) = I(U_i \geq u)$ . The survival model in (3) does not imply that the marginal HR of the potential survival outcomes under  $a = 1$  and  $a = 0$ , i.e.,  $\lambda_{10}(t)/\lambda_{00}(t)$ , is a constant and thus is not restrictive. Other survival models can be considered, including the additive hazards model (Lin and Ying, 1995; Aalen, 1989).

Chen and Tsiatis (2001) proposed a method that accounts for imbalances between treatment groups by first estimating the conditional treatment effect given  $X$  and then averaging the effect over  $X$  across both treatment groups. A similar approach can be applied to balance the covariate distribution between the RCT sample and the observational sample by first estimating the treatment-specific survival curve conditional on  $f(X | \delta = 1)$  under model (3), i.e.,  $\hat{S}_a(t | X_i) = \exp\{-\hat{\Lambda}_{ai}(t)\} = \exp\{-\hat{\Lambda}_{a0}(t) \exp(\hat{\beta}_a^T X_i)\}$ , and then applying the design-weighted averaging over  $f(X | \tilde{\delta} = 1)$ . The resulting outcome regression (OR) estimator of the marginal treatment-effect survival curve is

$$\hat{S}_a^{\text{OR}}(t) = \left( \sum_{i=1}^N \tilde{\delta}_i d_i \right)^{-1} \sum_{i=1}^N \tilde{\delta}_i d_i e^{-\hat{\Lambda}_{ai}(t)}, \quad (4)$$

for  $a \in \{0, 1\}$ , and the corresponding ATE estimator is defined as  $\hat{\theta}_\tau^{\text{OR}} = \Psi_\tau(\hat{S}_1^{\text{OR}}(t), \hat{S}_0^{\text{OR}}(t))$ . The OR estimator is consistent when the survival model (3) is correctly specified.

### 3.2 Inverse Probability and Calibration Weighting

We can construct the estimator of the marginal treatment-specific survival curve based on the identification formula in (2) that involves sampling score, treatment propensity score, and censoring



probability. This approach can be viewed as a combination of IPSW, inverse probability of treatment weighting (IPTW), and inverse probability of censoring weighting (IPCW). The weighting estimator requires positing models for the three probabilities and estimating them.

First, we consider the estimation of the sampling score. As the covariate distribution of the RCT sample is different from that of the target population in general, the estimated ATE based only on the RCT sample can be biased. A widely used approach to account for this selection bias is IPSW, i.e., weighting the RCT sample by the inverse probability of trial participation over that of observational study participation, to adjust for differences in covariate distribution between the trial sample and the population. Specifically,  $\pi_\delta(X)$  can be modeled as  $\pi_\delta(X) = \{\omega_{\text{IPSW}}(X)\}^{-1}$  where  $\omega_{\text{IPSW}}(X) = P(\tilde{\delta} = 1 \mid \delta + \tilde{\delta} = 1, X)/P(\delta = 1 \mid \delta + \tilde{\delta} = 1, X)$ . One can plug in  $\{\hat{\omega}_{\text{IPSW}}(X)\}^{-1}$  for  $\pi_\delta(X)$  in (2) using the common logistic regression model. However, the IPSW method requires the sampling score model to be correctly specified; it also could be highly unstable if  $P(\delta = 1 \mid \delta + \tilde{\delta} = 1, X)$  is close to zero for some  $X$ .

Instead of direct estimating the sampling scores, Lee et al. (2021) proposed the calibration weighting approach to reduce the selection bias in the trial-based estimator, which is analogous to the entropy balancing method by Hainmueller (2012) and more stable than the IPSW method. The basic idea is that subjects in the RCT sample are calibrated to the observational sample, so that after calibration, the covariate distribution of the RCT sample empirically matches that of the target population. The calibration weighting approach is based on the idea that for any  $\mathbf{g}(X)$ , the following identity hold,

$$E \left\{ \frac{\delta}{\pi_\delta(X)} \mathbf{g}(X) \right\} = E \left\{ \tilde{\delta} \mathbf{g}(X) \right\} = E \{ \mathbf{g}(X) \}, \quad (5)$$

where  $\mathbf{g}(X)$  is a function of  $X$  to be calibrated, e.g., the moments or any nonlinear transformations.

The calibration weights  $\omega_i$  are obtained by solving the optimization problem

$$\min_{\mathbf{w}} \sum_{i=1}^n \omega_i \log \omega_i, \quad (6)$$

$$\text{subject to } \omega_i \geq 0, \forall i, \sum_{i=1}^n \omega_i = 1, \text{ and } \sum_{i=1}^N \delta_i \omega_i \mathbf{g}(X_i) = \tilde{\mathbf{g}},$$

where  $\mathcal{W} = \{\omega_i : \delta_i = 1\}$ . The last constraint is the empirical representation of (5), where  $\tilde{\mathbf{g}} = \sum_{i=1}^N \tilde{\delta}_i d_i \mathbf{g}(X_i) / \sum_{i=1}^N \tilde{\delta}_i d_i$  is a consistent estimator of  $\mathbb{E}\{\mathbf{g}(X)\}$  from the observational sample. Minimizing the negative entropy function of the calibration weights in (6) enforces the weights to be as close to one another as possible, which reduces the variability due to heterogeneous weights. Using the Lagrange multiplier  $\boldsymbol{\lambda}$ , the objective function of this convex optimization problem becomes  $L(\boldsymbol{\lambda}, \mathcal{W}) = \sum_{i=1}^n \omega_i \log \omega_i - \boldsymbol{\lambda}^\top \{\sum_{i=1}^n \omega_i \mathbf{g}(X_i) - \tilde{\mathbf{g}}\}$ . The estimated calibration weights are  $\hat{\omega}_i = \omega(X_i; \hat{\boldsymbol{\lambda}}) = \exp\{\hat{\boldsymbol{\lambda}}^\top \mathbf{g}(X_i)\} / [\sum_{i=1}^n \exp\{\hat{\boldsymbol{\lambda}}^\top \mathbf{g}(X_i)\}]$ , where  $\hat{\boldsymbol{\lambda}}$  solves  $U(\boldsymbol{\lambda}) = \sum_{i=1}^n \exp\{\boldsymbol{\lambda}^\top \mathbf{g}(X_i)\} \{\mathbf{g}(X_i) - \tilde{\mathbf{g}}\} = 0$ . Under the loglinear sampling score model, the calibration weights from the objective function (6) have the same functional form as inverse probability of sampling score weights asymptotically, resulting in the direct correspondence between the calibration weight and the sampling score in that  $\hat{\omega}_i - \{N\hat{\pi}_\delta(X_i)\}^{-1} \xrightarrow{P} 0$ , as  $n \rightarrow \infty$  (Lee et al., 2021). Following that, we posit the loglinear sampling score model,

$$\pi_\delta(X) = \exp\{\eta_0^T \mathbf{g}(X)\}, \text{ for some } \eta_0. \quad (7)$$

Lee et al. (2021) showed that  $\hat{\boldsymbol{\lambda}}$  is equivalent to  $-\hat{\boldsymbol{\eta}}$ , where  $\hat{\pi}_\delta(X) = \pi_\delta(X; \hat{\boldsymbol{\eta}}) = \exp\{\hat{\boldsymbol{\eta}}^T \mathbf{g}(X)\}$ . Accordingly, in the rest of the paper, we represent the calibration weights using  $\hat{\boldsymbol{\eta}}$ , i.e.,  $\hat{\omega}_i = \omega(X_i; \hat{\boldsymbol{\eta}}) = \exp\{-\hat{\boldsymbol{\eta}}^T \mathbf{g}(X_i)\} / [\sum_{i=1}^n \exp\{-\hat{\boldsymbol{\eta}}^T \mathbf{g}(X_i)\}]$ . If one considers a logistic sampling score model instead, then other objective functions can be used, such as  $\sum_{i=1}^n (\omega_i - 1) \log(\omega_i - 1)$ , that corresponds to the weights with the same functional form as the inverse to a logistic probability of sampling (Zhao, 2019; Josey et al., 2020). However, the loglinear regression model in (7) is close to the logistic regression model when the proportion of the RCT sample in the target population is small.

With respect to treatment assignment,  $\pi_A(X)$  is generally known for RCTs. However, several authors suggested estimating the treatment propensity score for the RCTs in order to increase the efficiency and account for the chance of imbalance of prognostic variables (e.g., Williamson et al.,

2014; Colantuoni and Rosenblum, 2015). We choose a logistic regression model for the treatment propensity score,

$$\pi_A(X) = [1 + \exp\{-\rho_0^T \mathbf{g}(X)\}]^{-1}, \text{ for some } \rho_0, \quad (8)$$

and define  $\widehat{\pi}_{ai} = A_i \pi_A(X_i; \widehat{\rho}) + (1 - A_i) \{1 - \pi_A(X_i; \widehat{\rho})\}$ . Estimation of the propensity scores also broadens the scope of the current paper to allow generalization of the observational study results to its larger population which is analogous to a three-way balancing approach between the treated, the controlled, and the observational sample (Chan et al., 2016). Moreover, in order to account for right censoring  $C$ , we posit Cox proportional hazards model with conditional hazard

$$\lambda^C(t | X, A = a) = \lambda_{a0}^C(t) \exp(\gamma_a^T X), \text{ for } a \in \{0, 1\}, \quad (9)$$

where the standard techniques as for the survival model in (3) can be used to estimate  $\gamma_a$  and  $\Lambda_{a0}^C(t) \equiv \int_0^t \lambda_{a0}^C(u) du$ .

Combining  $\widehat{\omega}_i$ ,  $\widehat{\pi}_{ai}$ , and  $\widehat{\Lambda}_{ai}^C(t) = \widehat{\Lambda}_{a0}^C(t) \exp(\widehat{\gamma}_a^T X_i)$  estimated under the working models in (7), (8), and (9), respectively, we define the CW estimator of the marginal treatment-specific survival curve as

$$\widehat{S}_a^{CW}(t) = \sum_{i=1}^N \delta_i \widehat{\omega}_i \frac{A_{ai}}{\widehat{\pi}_{ai}} e^{\widehat{\Lambda}_{ai}^C(t)} Y_i(t), \quad (10)$$

where  $A_{ai} = I(A_i = a)$ . The corresponding ATE estimator is  $\widehat{\theta}_\tau^{CW} = \Psi_\tau \left( \widehat{S}_1^{CW}(t), \widehat{S}_0^{CW}(t) \right)$ .

## 4 Improved Estimators

### 4.1 Efficient Influence Function

Let  $\mathcal{O} = (X, A, U, \Delta, \delta, \widetilde{\delta})$  be one copy of the vector of *observed variables*. The OR estimator specified in (4) and the CW estimator specified in (10) use different components of the likelihood function  $f(\mathcal{O})$ . Specifically, the OR estimator is based on modeling  $S_a(t | X)$  for  $a \in \{0, 1\}$ , and the CW estimator is based on modeling  $\pi_\delta(X)$ ,  $\pi_a(X)$ , and  $S^C(t | A = 1, X)$  for  $a \in \{0, 1\}$ . These estimators are singly robust in that they are consistent only under the correct survival outcome

regression model or the correct weighting models. A vast number of estimators can be constructed by combining these two estimators. In general, the question becomes how to obtain the most efficient estimator. Our approach is to derive the EIF (Tsiatis, 2006) of  $\theta_\tau$  to construct semiparametrically efficient estimators. Such estimators also gain robustness to model misspecification as we show later.

We consider a class of influence functions of regular asymptotically linear (RAL) estimators of the treatment-specific survival curve  $S_a(t)$ . Define  $A_a = I(A = a)$  and  $\pi_a(X) = a\pi_A(X) + (1 - a)\{1 - \pi_A(X)\}$ . Following Tsiatis (2006), the class of observed data influence functions includes

$$\begin{aligned} \varphi_a(t; \mathcal{O}) &= \frac{\delta}{\pi_\delta(X)} \frac{A_a}{\pi_a(X)} \frac{Y(t)}{S^C(t | A = a, X)} - S_a(t) \\ &\quad + \underbrace{\frac{\delta}{\pi_\delta(X)} \{A - \pi_A(X)\} g_{a1}(X)}_{\text{an arbitrary score of } A | (X, \delta=1)} + \underbrace{\left\{ \frac{\delta}{\pi_\delta(X)} - \tilde{\delta} \right\} g_{a2}(X)}_{\text{an arbitrary score of } \delta | X} \\ &\quad + \underbrace{\frac{\delta}{\pi_\delta(X)} \frac{A_a}{\pi_a(X)} \int_0^t \frac{dM_a^C(u)}{S^C(u | A = a, X)} g_{a3}(u | A = a, X)}_{\text{an arbitrary score of } U, \Delta=0 | (X, A, \delta=1)} \end{aligned} \quad (11)$$

for arbitrary functions  $g_{a1}(\cdot)$ ,  $g_{a2}(\cdot)$ , and  $g_{a3}(\cdot)$ , where  $M_a^C(u) = N_a^C(u) - \int_0^u \Lambda_a^C(s) ds$  is a Martingale with  $N_a^C = A_a I(U \leq u, \Delta = 0)$ , and  $\Lambda_a^C(s)$  is a cumulative hazard for censoring for  $a \in \{0, 1\}$ . The last three terms in (11) are mean-zero functions. According to the semiparametric theory (Tsiatis, 2006), the EIF is the influence function in (11) with the smallest variance. The EIF can be derived by projecting the first term of (11) onto the orthogonal complement of the tangent space spanned by the scores of the nuisance functions, i.e., the last three terms. The RAL estimator with the EIF is a semiparametrically efficient estimator. The following theorem gives the EIF in the class of influence functions (11), with the proof given in the Appendix B.1.

**Theorem 1** *Under Assumptions 1–4, the EIF for the treatment-specific survival curve is*

$$\begin{aligned} \varphi_a^{\text{eff}}(t; \mathcal{O}) &= \frac{\delta}{\pi_\delta(X)} \frac{A_a}{\pi_a(X)} \frac{Y(t)}{S^C(t | A = a, X)} - S_a(t) \\ &\quad - \frac{\delta}{\pi_\delta(X)} \left\{ \frac{A - \pi_A(X)}{\pi_A(X)} \right\} \mathbb{E}\{I(T \geq t) | X, A = a, \delta = 1\} \end{aligned}$$

$$\begin{aligned}
& - \left\{ \frac{\delta}{\pi_\delta(X)} - \tilde{\delta}d \right\} \mathbb{E}\{I(T \geq t) \mid X, A = a, \delta = 1\} \\
& + \frac{\delta}{\pi_\delta(X)} \frac{A_a}{\pi_a(X)} \int_0^t \frac{dM_a^C(u)}{S^C(u \mid A = a, X)} \mathbb{E}\{I(T \geq u) \mid X, A = a, \delta = 1, U \geq u\}. \quad (12)
\end{aligned}$$

## 4.2 Augmented Calibration Weighting Estimator

Motivated by Theorem 1, under the survival model in (3) and the weighting models specified in (7)–(9), we propose the following augmented CW (ACW) estimator of the treatment-specific survival curve,

$$\begin{aligned}
\widehat{S}_a^{\text{ACW1}}(t) &= \sum_{i=1}^N \delta_i \widehat{\omega}_i \frac{A_{ai}}{\widehat{\pi}_{ai}} e^{\widehat{\Lambda}_{ai}^C(t)} Y_i(t) - \sum_{i=1}^N \delta_i \widehat{\omega}_i \left( \frac{A_{ai} - \widehat{\pi}_{ai}}{\widehat{\pi}_{ai}} \right) e^{-\widehat{\Lambda}_{ai}(t)} \\
& - \sum_{i=1}^N \left\{ \delta_i \widehat{\omega}_i - \left( \sum_{i=1}^N \tilde{\delta}_i d_i \right)^{-1} \tilde{\delta}_i d_i \right\} e^{-\widehat{\Lambda}_{ai}(t)} + \sum_{i=1}^N \delta_i \widehat{\omega}_i \frac{A_{ai}}{\widehat{\pi}_{ai}} \int_0^t \frac{d\widehat{M}_{ai}^C(u)}{e^{-\widehat{\Lambda}_{ai}^C(u)}} \frac{e^{-\widehat{\Lambda}_{ai}(t)}}{e^{-\widehat{\Lambda}_{ai}(u)}} \\
&= \sum_{i=1}^N \delta_i \widehat{\omega}_i \frac{A_{ai}}{\widehat{\pi}_{ai}} e^{\widehat{\Lambda}_{ai}^C(t)} Y_i(t) \\
& + \sum_{i=1}^N e^{-\widehat{\Lambda}_{ai}(t)} \left[ \left( \sum_{i=1}^N \tilde{\delta}_i d_i \right)^{-1} \tilde{\delta}_i d_i - \delta_i \widehat{\omega}_i \frac{A_{ai}}{\widehat{\pi}_{ai}} \left\{ 1 - \int_0^t \left\{ e^{\widehat{\Lambda}_{ai}^C(u) + \widehat{\Lambda}_{ai}(u)} \right\} d\widehat{M}_{ai}^C(u) \right\} \right]. \quad (13)
\end{aligned}$$

In addition, following the technique by Zhang and Schaubel (2012a) that represents the marginal cumulative hazard function  $\Lambda_a(t) = \int_0^t -\{S_a(u)\}^{-1} dS_a(u)$  by estimating the denominator and the numerator separately, we propose another ACW estimator,

$$\widehat{S}_a^{\text{ACW2}}(t) = \exp \left\{ - \int_0^t \frac{-d\widehat{S}_a^{\text{ACW1}}(u)}{\widehat{S}_a^{\text{ACW1}}(u)} \right\}, \quad (14)$$

where

$$\begin{aligned}
-d\widehat{S}_a^{\text{ACW1}}(u) &= \sum_{i=1}^N \delta_i \widehat{\omega}_i \frac{A_{ai}}{\widehat{\pi}_{ai}} e^{\widehat{\Lambda}_{ai}^C(u)} dN_i(u) \\
& + \sum_{i=1}^N e^{-\widehat{\Lambda}_{ai}(u)} d\widehat{\Lambda}_{ai}(u) \left[ \left( \sum_{i=1}^N \tilde{\delta}_i d_i \right)^{-1} \tilde{\delta}_i d_i - \delta_i \widehat{\omega}_i \frac{A_{ai}}{\widehat{\pi}_{ai}} \left\{ 1 - \int_0^u \left\{ e^{\widehat{\Lambda}_{ai}^C(s) + \widehat{\Lambda}_{ai}(s)} \right\} d\widehat{M}_{ai}^C(s) \right\} \right]
\end{aligned}$$

estimates  $-dS_a(u)$ . Although  $\widehat{S}_a^{\text{ACW1}}(t)$  and  $\widehat{S}_a^{\text{ACW2}}(t)$  are asymptotically equivalent, simulation studies show that  $\widehat{S}_a^{\text{ACW2}}(t)$  has better finite-sample performance. The proposed ACW estimators

are similar to the estimators developed by Zhang and Schaubel (2012b) and Zhang et al. (2019). The difference between the proposed and their method is discussed in Section 7.

Similar to Yang et al. (2020), we consider an asymptotic linear characterization of the ATE estimator  $\hat{\theta}_\tau^{\text{ACW}} = \Psi_\tau \left( \hat{S}_1^{\text{ACW}}(t), \hat{S}_0^{\text{ACW}}(t) \right)$  for both ACW1 and ACW2 estimators. That is, under mild regularity conditions,

$$\hat{\theta}_\tau^{\text{ACW}} - \theta_\tau = \int_0^\tau \phi_1(t) \left\{ \hat{S}_1^{\text{ACW}}(t) - S_1(t) \right\} dt + \int_0^\tau \phi_0(t) \left\{ \hat{S}_0^{\text{ACW}}(t) - S_0(t) \right\} dt + o_p(N^{-1/2}), \quad (15)$$

for some functions  $\phi_a(\cdot)$  that  $E\{\phi_a(\cdot)^2\} < \infty$ . Many survival estimands including the survival difference at a fixed time  $\tau$ , the difference of RMSTs, the ratio of RMTLs, and the difference of  $\tau$ th quantile of survivals can be represented under this asymptotic linear characterization (see Appendix A for details). The following corollary gives the EIF of the ATE with the proof given in the Appendix B.2.

**Corollary 1** *Under the asymptotic linear characterization in (15), the EIF for  $\theta_\tau$  is*

$$\varphi_{\theta_\tau}^{\text{eff}}(\mathcal{O}) = \int_0^\tau \phi_1(t) \varphi_1^{\text{eff}}(t; \mathcal{O}) dt + \int_0^\tau \phi_0(t) \varphi_0^{\text{eff}}(t; \mathcal{O}) dt.$$

We now show the local efficiency and asymptotic properties of the proposed ACW estimators of the ATE, i.e.,  $\hat{\theta}_\tau^{\text{ACW1}} = \Psi_\tau \left( \hat{S}_1^{\text{ACW1}}(t), \hat{S}_0^{\text{ACW1}}(t) \right)$  and  $\hat{\theta}_\tau^{\text{ACW2}} = \Psi_\tau \left( \hat{S}_1^{\text{ACW2}}(t), \hat{S}_0^{\text{ACW2}}(t) \right)$ .

**Theorem 2** *Under Assumptions 1–4, if either the survival model in (3) is correctly specified or the weighting models, i.e., the sampling score model (7), the treatment propensity score model (8), and the censoring model (9), are correctly specified, under regularity conditions,  $\hat{\theta}_\tau^{\text{ACW1}}$  and  $\hat{\theta}_\tau^{\text{ACW2}}$  are consistent for  $\theta_\tau$ , and  $N^{1/2}(\hat{\theta}_\tau^{\text{ACW1}} - \theta_\tau)$  and  $N^{1/2}(\hat{\theta}_\tau^{\text{ACW2}} - \theta_\tau)$  are asymptotically normal with mean zero and variance  $E(\varsigma_1^2)$  and  $E(\varsigma_2^2)$ . Moreover, if all working models in (3) and (7)–(9) are correctly specified,  $\hat{\theta}_\tau^{\text{ACW1}}$  and  $\hat{\theta}_\tau^{\text{ACW2}}$  are locally efficient, i.e.,  $\varsigma_1 = \varsigma_2 = \varphi_{\theta_\tau}^{\text{eff}}(\mathcal{O})$  as  $n \rightarrow \infty$ .*

The proof of Theorem 2 and details of  $\varsigma_1^2$  and  $\varsigma_2^2$  are provided in the Appendix B.3. For a straightforward procedure of variance estimation, a nonparametric bootstrap method can be used.

## 5 Simulation Studies

In this section, we conduct simulation studies to evaluate the finite-sample performance of the proposed estimators. We consider the target population of size  $N = 200,000$  and covariates  $X = (X_1, X_2, X_3)^T$ , where each  $X_i, i = 1, 2, 3$  is generated from  $N(0, 1)$  and truncated at  $-4$  and  $4$  to satisfy regularity conditions. From a hypothetical RCT eligible population with size  $N_1 = 50,000$ , we generate the indicator of RCT participation according to  $\log\{\pi_\delta(X)\} = -4.7 - 0.5X_1 - 0.5X_2 - 0.3X_3$ , which results in an RCT sample of size  $n \sim 650$ . From the remaining  $N_2 = 150,000$  observational study population, we randomly select a sample of size  $m = 5,000$ .

We consider the difference in RMST as the ATE, i.e.,  $\theta_\tau = \Psi_\tau(S_1(t), S_0(t)) = \int_0^\tau \{S_1(t) - S_0(t)\} dt = \int_0^\tau S_1(t)dt - \int_0^\tau S_0(t)dt = \mu_{1,\tau} - \mu_{0,\tau}$ , where we choose  $\tau = 20$ . We compare the proposed CW and the ACW estimators with four other methods, the Naive estimator based only on the RCT sample, the ZS estimator, i.e., the estimator proposed by Zhang and Schaubel (2012b) based only on the RCT sample, the IPSW estimator using the normalized IPSW weight in (10), and the OR estimator specified in (4). To assess the performance of these estimators under model misspecification, we consider four scenarios where i) all four models in (3) and (7)–(9) are correct, ii) only the survival outcome model (3) is correct, iii) the outcome model is incorrect but the other three weighting models (7)–(9) are correct, iv) all four models are incorrect. Details of estimators and specification of the four working models when they are correctly/incorrectly specified are listed in Table 1.

Table 2 and Figure 2 summarize the results based on 1000 Monte Carlo replications. The bootstrap variance estimation was used for all estimators with  $B = 100$ . When all models are correctly specified, the Naive and ZS estimators which are based only on the RCT sample show biased estimations of the ATE due to the selection bias in the RCT sample. The OR, IPSW, CW, ACW1, and ACW2 estimators correct that bias by leveraging the observational sample covariates. Both ACW estimators were found to be more efficient than other unbiased IPW estimators. Even though the variance of the OR estimator is smaller, it is biased when the outcome model is incorrectly spec-

Table 1: Simulation settings: model specification and estimators;  $\text{expit}(x) = \{1 + \exp(-x)\}^{-1}$ . O: survival outcome, S: sampling score, A: treatment propensity score, C: censoring

Models	Correctly specified	Incorrectly specified	
O	$\lambda_1(t   X)$	$t \exp(-3.7) \exp(-X_1 - X_2 - 1.5X_3)$	$t \exp(-0.8) \exp(-e^{X_1} - e^{X_2} - 1.5X_3)$
	$\lambda_0(t   X)$	$t \exp(-3) \exp(-1.8X_1 - 1.5X_2 - X_3)$	$t \exp(1.5) \exp(-1.8e^{X_1} - 1.5e^{X_2} - X_3)$
S	$\pi_\delta(X)$	$\text{expit}\{-4.7 - 0.5X_1 - 0.5X_2 - 0.3X_3\}$	$\text{expit}\{-4.7 - 0.5e^{X_1} - 0.5e^{X_2} - 0.3X_3\}$
A	$\pi_A(X)$	0.5	$\text{expit}\{-1 + 0.5e^{X_1} + 0.5e^{X_2} - 0.5e^{X_3}\}$
C	$\lambda_1^C(t   X)$	$t \exp(-4.5) \exp(-0.5X_1 - X_2 - X_3)$	$t \exp(-2.5) \exp(-0.5e^{X_1} - e^{X_2} - X_3)$
	$\lambda_0^C(t   X)$	$t \exp(-3.5) \exp(-0.5X_1 - X_2 - X_3)$	$t \exp(-1.5) \exp(-0.5e^{X_1} - e^{X_2} - X_3)$

Estimators	Details
Naive	$\hat{\theta}_\tau^{\text{Naive}} = \int_0^\tau \left\{ \hat{S}_1^{\text{Naive}}(t) - \hat{S}_0^{\text{Naive}}(t) \right\} dt$ , where $\hat{S}_a^{\text{Naive}}(t) = n^{-1} \sum_{i=1}^N \delta_i A_{ai} \{\hat{\pi}_{ai}\}^{-1} e^{\hat{\Lambda}_{ai}^C(t)} Y_i(t)$
ZS	The denominator of the estimator proposed by Zhang and Schaubel (2012b)
OR	$\hat{\theta}_\tau^{\text{OR}} = \int_0^\tau \left\{ \hat{S}_1^{\text{OR}}(t) - \hat{S}_0^{\text{OR}}(t) \right\} dt$ , where $\hat{S}_a^{\text{OR}}(t)$ is defined by (4)
IPSW	$\hat{\theta}_\tau^{\text{IPSW}} = \int_0^\tau \left\{ \hat{S}_1^{\text{IPSW}}(t) - \hat{S}_0^{\text{IPSW}}(t) \right\} dt$ , where $\hat{S}_a^{\text{IPSW}}(t) = \sum_{i=1}^N \delta_i \hat{\omega}_i^{\text{IPSW}} A_{ai} \{\hat{\pi}_{ai}\}^{-1} e^{\hat{\Lambda}_{ai}^C(t)} Y_i(t)$
CW	$\hat{\theta}_\tau^{\text{CW}} = \int_0^\tau \left\{ \hat{S}_1^{\text{CW}}(t) - \hat{S}_0^{\text{CW}}(t) \right\} dt$ where $\hat{S}_a^{\text{CW}}(t)$ is defined by (10)
ACW1	$\hat{\theta}_\tau^{\text{ACW1}} = \int_0^\tau \left\{ \hat{S}_1^{\text{ACW1}}(t) - \hat{S}_0^{\text{ACW1}}(t) \right\} dt$ where $\hat{S}_a^{\text{ACW1}}(t)$ is defined by (13)
ACW2	$\hat{\theta}_\tau^{\text{ACW2}} = \int_0^\tau \left\{ \hat{S}_1^{\text{ACW2}}(t) - \hat{S}_0^{\text{ACW2}}(t) \right\} dt$ where $\hat{S}_a^{\text{ACW2}}(t)$ is defined by (14)

ified. The CW and IPSW estimators are biased when the sampling score model is not correctly specified. The proposed ACW estimators are double robust when either the outcome model or the other three models are correctly specified. The ACW2 estimator was found to be more consistent than the ACW1 in a finite sample.



Table 2: Simulation results under four scenarios; T: True (correct) model, W: Wrong (incorrect) model. Bias is the empirical bias of point estimates; ESE is the empirical standard error of estimates; RSE is the relative bias (%) of bootstrap standard error estimates; CP is the empirical coverage probability of the 95% confidence intervals.

Estimator	BIAS			ESE			RSE(%)			CP(%)		
	$\mu_1$	$\mu_0$	$\theta$	$\mu_1$	$\mu_0$	$\theta$	$\mu_1$	$\mu_0$	$\theta$	$\mu_1$	$\mu_0$	$\theta$
Scenario 1: O:T / S:T, A:T, C:T												
Naive	-4.18	-4.87	0.70	0.42	0.42	0.46	1.39	1.53	-3.78	0.0	0.1	68.7
ZS	-4.18	-4.88	0.69	0.42	0.39	0.42	2.92	0.71	-2.23	0.0	0.0	65.6
IPSW	0.07	0.03	0.04	0.44	0.56	0.71	-3.89	-2.42	-3.70	95.1	94.3	95.9
CW	0.14	0.13	0.01	0.45	0.52	0.71	-1.09	-3.37	-3.54	93.4	93.3	95.5
OR	0.03	0.01	0.02	0.31	0.32	0.43	-1.09	-0.60	-1.94	94.3	94.3	95.3
ACW1	0.08	0.09	-0.01	0.34	0.37	0.49	-2.89	-3.22	-3.78	94.9	92.9	95.5
ACW2	0.02	0.02	0.00	0.34	0.37	0.49	-2.44	-2.58	-3.31	96.0	94.3	95.4
Scenario 2: O:T / S:W, A:W, C:W												
Naive	-3.90	-4.97	1.06	0.48	0.49	0.60	1.61	-0.96	2.28	0.0	0.0	52.6
ZS	-3.88	-4.74	0.86	0.44	0.42	0.51	2.72	-1.43	3.23	0.0	0.0	57.7
IPSW	-0.34	-1.34	1.00	0.43	0.63	0.77	-0.31	-3.19	-0.20	88.2	44.3	71.0
CW	0.53	-0.08	0.61	0.44	0.79	0.92	0.90	0.51	1.07	75.0	94.1	87.8
OR	0.03	0.01	0.01	0.30	0.32	0.45	-0.30	-2.73	2.24	94.5	95.5	93.9
ACW1	0.08	0.11	-0.03	0.35	0.48	0.59	1.23	-0.59	2.53	93.7	93.6	94.4
ACW2	0.03	0.04	-0.02	0.35	0.47	0.59	1.66	-2.73	1.08	94.5	94.0	94.3
Scenario 3: O:W / S:T, A:T, C:T												
Naive	-4.06	-4.71	0.65	0.42	0.44	0.52	-2.90	-0.50	-2.84	0.0	0.2	74.7
ZS	-4.06	-4.70	0.63	0.42	0.41	0.49	-0.22	-0.20	0.77	0.0	0.00	73.1
IPSW	0.05	-0.03	0.08	0.47	0.61	0.77	-4.39	-2.60	-3.75	95.5	94.4	95.8
OR	-0.40	-0.87	0.48	0.36	0.41	0.53	-1.22	0.38	-0.62	81.8	43.5	86.0
CW	0.12	0.07	0.05	0.46	0.56	0.78	-1.98	-4.11	-2.96	94.5	95.8	95.7
ACW1	0.07	0.06	0.01	0.36	0.40	0.54	-2.16	-3.81	-2.56	94.6	95.2	94.9
ACW2	0.02	-0.01	0.03	0.36	0.40	0.54	-2.09	-6.74	-4.79	95.2	95.0	94.8
Scenario 4: O:W / S:W, A:W, C:W												
Naive	-4.08	-5.56	1.48	0.50	0.46	0.63	0.37	-3.28	-0.32	0.1	0.0	33.8
ZS	-4.13	-5.43	1.30	0.46	0.41	0.55	2.52	-1.98	3.68	0.1	0.0	30.9
IPSW	-0.71	-2.34	1.63	0.48	0.67	0.83	1.52	-4.67	-1.53	68.4	11.4	50.9
CW	0.18	-1.14	1.31	0.48	0.84	1.01	1.80	-0.94	-0.38	93.1	66.5	72.0
OR	-0.73	-2.15	1.42	0.35	0.45	0.58	0.64	1.90	4.91	45.7	0.0	29.0
ACW1	-0.26	-0.77	0.51	0.37	0.55	0.67	1.62	-2.49	-0.25	89.6	69.6	86.3
ACW2	-0.31	-0.84	0.52	0.37	0.55	0.67	2.13	-5.66	-2.61	87.3	65.0	85.5




Figure 2: Boxplot of estimators under four model specification scenarios; T: True (correct) model, W: Wrong (incorrect) model.

## 6 Real Data Application

We apply the proposed method to estimate the effect of adjuvant chemotherapy on survival in patients with early-stage resected non-small cell lung cancer (NSCLC). Cancer and Leukemia Group B (CALGB) 9633 is the only randomized phase III trial designed to evaluate the effectiveness of adjuvant chemotherapy over observation for stage IB NSCLC (Strauss et al., 2008). An additional observational sample for stage IB NSCLC patients was extracted from National Cancer Database (NCDB), including more than 15,000 patients with the same eligibility criteria as CALGB 9633. More details of the two data sources are given in Lee et al. (2021), where they conducted an inte-

Table 3: Baseline characteristics of the CALGB 9633 trial sample and the NCDB sample; mean (standard deviation) for continuous and number (proportion) for binary covariate.

	Male ( $X_1$ )	Age ( $X_2$ )	Squamous histology ( $X_3$ )	Tumor size ( $X_4$ )
RCT: CALGB 9633 ( $n = 319$ )	204 (64%)	60.83 (9.62)	128 (40%)	4.6 (2.08)
OS: NCDB ( $n = 15379$ )	8458 (55%)	67.87 (10.18)	5998 (39%)	4.94 (3.04)

grative analysis of the CALGB trial sample and the NCDB sample to improve generalizability for the CALGB 9633 trial-based estimator of average risk of cancer recurrence.

Table 3 summarizes the distribution of the four baseline covariates by the data sources, which have been considered important prognostic factors. The baseline covariates of the patients in the CALGB trial are different from those of the patients in NCDB. Specifically, the CALGB trial patients consist of more males, are younger, and have smaller tumor sizes. Consequently, an important clinical question is whether adjuvant chemotherapy benefits the general stage IB NSCLC patients population, represented by the NCDB, which is a population-based registry capturing approximately 79 percent of newly diagnosed lung cancers in the United States, and contains more females, are older, and have larger tumor sizes than the CALGB patients. Given that the RCT sample is relatively healthier than the NCDB sample, the estimators based only on CALGB 9633 sample would result in biased estimation of the true effect of adjuvant chemotherapy on the real-world population of early-stage NSCLC patients.

We estimate a 12-year difference of the restricted mean lifetime between adjuvant chemotherapy and observation (i.e., no chemotherapy). The nonparametric bootstrap method is used to estimate the standard errors. The results are given in Table 4, using the proposed estimators and other existing methods in the simulation studies. The Naive and ZS estimators indicate that in the RCT sample, there is no 12-year RMST difference between the adjuvant chemotherapy and observation, i.e., 0.02 and 0.04 years, respectively. All other estimators that utilize the covariate information of the observational study show a much larger difference in the RMST. The IPSW and CW estimators

Table 4: Estimates and 95% confidence intervals of 12-year difference of the restricted mean lifetime between adjuvant chemotherapy and observation.

Estimator	$\widehat{\mu}_1$	$\widehat{\mu}_0$	$\widehat{\theta}$
Naive	3.33 (2.86, 3.94)	3.31 (2.81, 3.92)	0.022 (-0.815, 0.895)
ZS	3.34 (2.89, 3.94)	3.30 (2.79, 3.90)	0.044 (-0.794, 0.881)
IPSW	3.71 (3.09, 4.55)	3.23 (2.62, 3.83)	0.478 (-0.339, 1.550)
CW	3.73 (3.07, 4.69)	3.17 (2.49, 3.87)	0.561 (-0.363, 1.830)
OR	3.88 (3.17, 4.69)	3.04 (2.37, 3.61)	0.835 (-0.160, 1.890)
ACW1	4.07 (3.35, 5.00)	3.10 (2.41, 3.64)	0.967 (0.043, 2.100)
ACW2	4.14 (3.42, 5.17)	3.13 (2.45, 3.64)	1.01 (0.048, 2.200)

show about 0.4–0.5 year increase in RMST for adjuvant chemotherapy over observation, and the OR estimator show about 0.84 year increase; however, these estimates are not significant. The proposed ACW1 and ACW2 estimators give an estimate of about a 1-year RMST increase for patients who received adjuvant chemotherapy, which is significant at 0.05 level. Figure 3 represents the estimated restricted mean lifetime for adjuvant chemotherapy and observation and their difference as a function of restricted times  $\tau$ . All selection-bias-adjusted estimators, i.e., the IPSW, CW, OR, ACW1, and ACW2 estimators, show a trend of increasing RMST difference over  $\tau$  for all  $\tau$  from 1 to 13 years. Especially, the ACW1 and ACW2 estimators show significant non-zero differences when  $\tau$  is large. On the other hand, the Naive and ZS estimators which are based only on the RCT sample show nearly flat trends near zero difference over  $\tau$ . All these results indicate that the proposed estimators are able to detect the effect of adjuvant chemotherapy on survival in the real world population than that in the RCT sample with higher efficiency and more protection against model misspecification, by leveraging the information from the observational study.




Figure 3: Estimated RMST plots of adjuvant chemotherapy and observation and their difference as a function of restricted times.

## 7 Discussion

This paper considers a framework to estimate the treatment effect defined as a function of the treatment-specific survival probability function. The proposed ACW estimators are motivated by two identification formulas based on the survival outcome model and the weighting models and achieve local efficiency and double robustness based on semiparametric theory.

The proposed ACW estimators are similar to the estimator proposed by Zhang and Schaubel (2012b) that combines the treatment-specific Cox model by Chen and Tsiatis (2001) and the inverse probability of treatment weighted Nelson-Aalen method proposed by Wei (2008). However, unlike our estimator that is derived from the EIF, their approach is based on augmenting the IPW estimating equation to achieve double robustness, and the efficiency of their estimator has not been studied yet. Moreover, their estimator is based only on the RCT sample, whereas we leverage the observational sample to account for selection bias, resulting in an additional augmentation in terms of the sampling score model. In addition, we focus on the class of estimands defined as functionals of the survival functions, including the framework proposed by Zhang and Schaubel (2012b) as a special case.

The proposed approach is also similar to Zhang et al. (2019), focusing on the broad class of Mann-Whitney-type causal effect based on semiparametric theory. To derive the EIF, they construct a RAL estimator that excludes censored data. In contrast, by restricting our interest to the functional of the treatment-specific survival curves, we consider a different RAL estimator utilizing both observed and censored data. The proposed class of estimators could be more robust under highly censored data and covers a broad class of estimands that are favored in time-to-event data.

The proposed methods assume that the trial participation is ignorable, i.e., all covariates related to the trial participation and survival time are captured. However, some important covariates might not be available in the observational samples as there were not originally collected for the research purpose. Future work could involve a sensitivity analysis assessing the robustness of

the proposed framework in the presence of unmeasured covariates in observational studies (e.g., VanderWeele and Ding, 2017; Yang and Lok, 2017).

The robustness of the proposed estimators can be improved with machine learning methods. For example, a penalized Cox PH model can be used combined with a nonparametric Sieve method (Lee et al., 2021) or Bernstein polynomials (Osman and Ghosh, 2012). Survival trees can be used alternative to the Cox proportional hazard model (Bou-Hamad et al., 2011). We will incorporate machine learning techniques into the proposed framework to add great flexibility and consistency.

In addition to the estimation of the ATE, a key challenge is to identify subgroups of patients for whom the treatment is more effective. Estimating individualized treatment effects is a key toward precision medicine so that doctors can tailor treatment for individual patients given their characteristics. Interesting future research would be generalizing individualized treatment effects for survival outcomes combining RCT and observational studies, following Yang et al. (2020a,b) and Wu and Yang (2021).

## References

- Aalen, O. O. (1989). A linear regression model for the analysis of life times. *Statistics in medicine* 8(8), 907–925.
- Bickel, P. J., C. A. Klaassen, P. J. Bickel, Y. Ritov, J. Klaassen, J. A. Wellner, and Y. Ritov (1993). *Efficient and adaptive estimation for semiparametric models*, Volume 4. Johns Hopkins University Press Baltimore.
- Bou-Hamad, I., D. Larocque, and H. Ben-Ameur (2011). A review of survival trees. *Statistics surveys* 5, 44–71.
- Breslow, N. (1974). Covariance analysis of censored survival data. *Biometrics*, 89–99.
- Chan, K. C. G., S. C. P. Yam, and Z. Zhang (2016). Globally efficient non-parametric inference

- of average treatment effects by empirical balancing calibration weighting. *Journal of the Royal Statistical Society. Series B, Statistical methodology* 78(3), 673–700.
- Chen, P.-Y. and A. A. Tsiatis (2001). Causal inference on the difference of the restricted mean lifetime between two groups. *Biometrics* 57(4), 1030–1038.
- Colantuoni, E. and M. Rosenblum (2015). Leveraging prognostic baseline variables to gain precision in randomized trials. *Statistics in medicine* 34(18), 2602–2617.
- Cole, S. R. and M. A. Hernán (2004). Adjusted survival curves with inverse probability weights. *Computer methods and programs in biomedicine* 75(1), 45–49.
- Cole, S. R. and E. A. Stuart (2010). Generalizing evidence from randomized clinical trials to target populations: the actg 320 trial. *American journal of epidemiology* 172(1), 107–115.
- Colnet, B., I. Mayer, G. Chen, A. Dieng, R. Li, G. Varoquaux, J.-P. Vert, J. Josse, and S. Yang (2020). Causal inference methods for combining randomized trials and observational studies: a review. *arXiv preprint arXiv:2011.08047*.
- Dahabreh, I. J., S. E. Robertson, E. J. Tchetgen, E. A. Stuart, and M. A. Hernán (2019). Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals. *Biometrics* 75, 685–694.
- Francisco, C. A. and W. A. Fuller (1991). Quantile estimation with a complex survey design. *The Annals of statistics*, 454–469.
- Hainmueller, J. (2012). Entropy balancing for causal effects: A multivariate reweighting method to produce balanced samples in observational studies. *Political Analysis* 20(1), 25–46.
- Hartman, E., R. Grieve, R. Ramsahai, and J. S. Sekhon (2015). From sample average treatment effect to population average treatment effect on the treated: combining experimental with obser-



- vational studies to estimate population treatment effects. *Journal of the Royal Statistical Society. Series A (Statistics in Society)*, 757–778.
- Hernán, M. A. (2010). The hazards of hazard ratios. *Epidemiology (Cambridge, Mass.)* 21(1), 13.
- Josey, K. P., E. Juarez-Colunga, F. Yang, and D. Ghosh (2020). A framework for covariate balance using bregman distances. *Scand J Stat* 48(3), 790–816.
- Kennedy, E. H. (2016). Semiparametric theory and empirical processes in causal inference. In *Statistical causal inferences and their applications in public health research*, pp. 141–167. Springer.
- Lee, D., S. Yang, L. Dong, X. Wang, D. Zeng, and J. Cai (2021). Improving trial generalizability using observational studies. *Biometrics*.
- Lin, D. and Z. Ying (1995). Semiparametric analysis of general additive-multiplicative hazard models for counting processes. *The annals of Statistics*, 1712–1734.
- Lin, D. Y. and L.-J. Wei (1989). The robust inference for the cox proportional hazards model. *Journal of the American statistical Association* 84(408), 1074–1078.
- Osman, M. and S. K. Ghosh (2012). Nonparametric regression models for right-censored data using bernstein polynomials. *Computational Statistics & Data Analysis* 56(3), 559–573.
- Pan, Q. and D. E. Schaubel (2008). Proportional hazards models based on biased samples and estimated selection probabilities. *Canadian Journal of Statistics* 36(1), 111–127.
- Robins, J. M., A. Rotnitzky, and L. P. Zhao (1995). Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. *Journal of the american statistical association* 90(429), 106–121.
- Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of educational Psychology* 66(5), 688.

- Rubin, D. B. (1986). Comment: Which ifs have causal answers. *Journal of the American statistical association* 81(396), 961–962.
- Strauss, G. M., J. E. Herndon, M. A. M. II, D. W. Johnstone, E. A. Johnson, D. H. Harpole, H. H. Gillenwater, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, et al. (2008). Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non–small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J. Clin. Oncol.* 26(31), 5043–5051.
- Stuart, E. A., S. R. Cole, C. P. Bradshaw, and P. J. Leaf (2011). The use of propensity scores to assess the generalizability of results from randomized trials. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 174(2), 369–386.
- Tipton, E. (2013). Improving generalizations from experiments using propensity score subclassification: Assumptions, properties, and contexts. *Journal of Educational and Behavioral Statistics* 38(3), 239–266.
- Trinquart, L., J. Jacot, S. C. Conner, and R. Porcher (2016). Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. *Journal of Clinical Oncology* 34(15), 1813–1819.
- Tsiatis, A. A. (2006). *Semiparametric theory and missing data*. Springer.
- Van der Vaart, A. W. (2000). *Asymptotic statistics*, Volume 3. Cambridge university press.
- Van Der Vaart, A. W., A. W. van der Vaart, A. van der Vaart, and J. Wellner (1996). *Weak convergence and empirical processes: with applications to statistics*. Springer Science & Business Media.
- VanderWeele, T. J. and P. Ding (2017). Sensitivity analysis in observational research: introducing the e-value. *Annals of internal medicine* 167(4), 268–274.

- Wei, G. (2008). *Semiparametric methods for estimating cumulative treatment effects in the presence of non-proportional hazards and dependent censoring*. University of Michigan.
- Wei, G. and D. E. Schaibel (2008). Estimating cumulative treatment effects in the presence of nonproportional hazards. *Biometrics* 64(3), 724–732.
- Williamson, E. J., A. Forbes, and I. R. White (2014). Variance reduction in randomised trials by inverse probability weighting using the propensity score. *Statistics in medicine* 33(5), 721–737.
- Wu, L. and S. Yang (2021). Transfer learning of individualized treatment rules from experimental to real-world data. *arXiv preprint arXiv:2108.08415*.
- Yang, S. and J. J. Lok (2017). Sensitivity analysis for unmeasured confounding in coarse structural nested mean models. *Statistica Sinica* 28, 1703–1723.
- Yang, S., D. Zeng, and X. Wang (2020a). Elastic integrative analysis of randomized trial and real-world data for treatment heterogeneity estimation. *arXiv preprint arXiv:2005.10579*.
- Yang, S., D. Zeng, and X. Wang (2020b). Improved inference for heterogeneous treatment effects using real-world data subject to hidden confounding. *arXiv preprint arXiv:2007.12922*.
- Yang, S., Y. Zhang, G. F. Liu, and Q. Guan (2020). Smim: a unified framework of survival sensitivity analysis using multiple imputation and martingale. *arXiv preprint arXiv:2007.02339*.
- Zhang, M. and D. E. Schaibel (2012a). Contrasting treatment-specific survival using double-robust estimators. *Statistics in medicine* 31(30), 4255–4268.
- Zhang, M. and D. E. Schaibel (2012b). Double-robust semiparametric estimator for differences in restricted mean lifetimes in observational studies. *Biometrics* 68(4), 999–1009.
- Zhang, Z., C. Liu, S. Ma, and M. Zhang (2019). Estimating mann–whitney-type causal effects for right-censored survival outcomes. *Journal of Causal Inference* 7(1).

Zhao, Q. (2019). Covariate balancing propensity score by tailored loss functions. *The Annals of Statistics* 47(2), 965–993.

# Appendix

## A Asymptotic linear characterization of survival estimands

Let  $\widehat{S}_a(t)$  be an estimator of a treatment-specific survival curve  $S_a(t)$  such that  $\widehat{S}_a(t) - S_a(t) = o_p(N^{-1/2})$  for  $a \in \{0, 1\}$ . Following Yang et al. (2020), under mild regularity conditions, all survival estimands mentioned in the main paper have the following asymptotic linear characterizations,

$$\widehat{\theta}_\tau - \theta_\tau = \int_0^\tau \phi_1(t) \left\{ \widehat{S}_1(t) - S_1(t) \right\} dt + \int_0^\tau \phi_0(t) \left\{ \widehat{S}_0(t) - S_0(t) \right\} dt + o_p(N^{-1/2}),$$

where  $\widehat{\theta}_\tau = \Psi_\tau \left( \widehat{S}_1(t), \widehat{S}_0(t) \right)$ .

1. Difference in the survival at a time point  $\tau$ :

$$\widehat{\theta}_\tau = \widehat{S}_1(\tau) - \widehat{S}_0(\tau) \implies \phi_1(t) = I(t = \tau) \text{ and } \phi_0(t) = -I(t = \tau).$$

2. Difference in RMSTs up to  $\tau$ :

$$\widehat{\theta}_\tau = \int_0^\tau \widehat{S}_1(\tau) dt - \int_0^\tau \widehat{S}_0(\tau) dt \implies \phi_1(t) = 1 \text{ and } \phi_0(t) = -1.$$

3. Ratio of RMTLs up to  $\tau$ :

$$\begin{aligned} \widehat{\theta}_\tau &= \left\{ \tau - \int_0^\tau \widehat{S}_1(\tau) dt \right\} / \left\{ \tau - \int_0^\tau \widehat{S}_0(\tau) dt \right\}. \\ \implies \phi_1(t) &= - \left\{ \tau - \int_0^\tau \widehat{S}_0(\tau) dt \right\}^{-1} \text{ and } \phi_0(t) = -\widehat{\theta}_\tau \left\{ \tau - \int_0^\tau \widehat{S}_0(\tau) dt \right\}^{-1} \text{ by the Taylor expansion.} \end{aligned}$$

4. Difference in  $\tau$ th quantile of survivals:

$$\theta = q_{1,\tau} - q_{0,\tau} \text{ and } \widehat{\theta} = \widehat{q}_{1,\tau} - \widehat{q}_{0,\tau} \text{ where } q_{a,\tau} = \inf_q \{ S_a(q) \leq \tau \} \text{ and } \widehat{q}_{a,\tau} = \inf_q \{ \widehat{S}_a(q) \leq \tau \}.$$

Following the Bahadur-type representation, under regularity conditions (Francisco and Fuller, 1991),  $\widehat{q}_{a,\tau}$  can be expressed as

$$\widehat{q}_{a,\tau} - q_{a,\tau} = \frac{\widehat{S}_a(q_{a,\tau}) - S_a(q_{a,\tau})}{\dot{S}_a(q_{a,\tau})} + o_p(N^{-1/2}),$$

where  $\dot{S}_a(q_{a,\tau}) = dS_a(q)/dq$ .

$$\implies \phi_1(t) = \left\{ \dot{S}_1(q_{1,\tau}) \right\}^{-1} I(t = q_{1,\tau}) \text{ and } \phi_0(t) = \left\{ \dot{S}_0(q_{0,\tau}) \right\}^{-1} I(t = q_{0,\tau}).$$

## B Proofs

### B.1 Proof of Theorem 1

We first derive the efficient influence function (EIF) for treatment-specific survival curves without censoring, i.e., under full data set  $\mathcal{V} = (X, A, T, \delta, \tilde{\delta})$ , then derive it in the presence of censoring, i.e., under the observed data set  $\mathcal{O} = (X, A, U, \Delta, \delta, \tilde{\delta})$ . The proof based on  $\mathcal{V}$  is similar to the one in Lee et al. (2021) using the method of parametric submodel (Bickel et al., 1993). We use  $\xi$  in the subscript to denote the submodel. For example,  $f_\xi(\mathcal{V})$  is a one-dimensional parametric submodel with the true  $f(\mathcal{V})$  at  $\xi = 0$ , i.e.,  $f_\xi(\mathcal{V})|_{\xi=0} = f(\mathcal{V})$ .

Since the likelihood of a single  $\mathcal{V}$  is

$$f(\mathcal{V}) = \{f(X)f(\delta = 1 | X)f(A | X, \delta = 1)f(T | X, A, \delta = 1)\}^\delta \{f(X)\}^{\tilde{\delta}}$$

and  $\delta\tilde{\delta} = 0$ , the score function can be decomposed as

$$\dot{S}(\mathcal{V}) = \delta\dot{S}(X) + \delta\dot{S}(\delta | X) + \delta\dot{S}(A | X, \delta = 1) + \delta\dot{S}(T | X, A, \delta = 1) + \tilde{\delta}\dot{S}(X).$$

We use  $\dot{S}$  to represent the score function.

The nuisance tangent space from the semiparametric theory is

$$H = H_1 \oplus H_2 \oplus H_3 \oplus H_4$$

where

$$H_1 = \{h(X) : \mathbb{E}\{h(X)\} = 0\}$$

$$H_2 = \{h(X, \delta) : \mathbb{E}\{h(\delta, X) | X\} = 0\}$$

$$H_3 = \{h(A, \delta, X) : \mathbb{E}\{h(A, \delta, X) | \delta, X\} = 0\}$$

$$H_4 = \{h(T, A, \delta, X) : \mathbb{E}\{h(T, A, \delta, X) | A, \delta, X\} = 0\}.$$

Here we only derive the EIF for  $S_1(u)$ . The EIF for  $S_0(u)$  can be easily derived using the similar technique. We denote the EIF for  $S_1(u)$  under  $\mathcal{V}$  as  $\varphi_1^F(u | \mathcal{V})$  which must satisfy  $\varphi_1^F(u | \mathcal{V}) \in H$

and  $\frac{\partial}{\partial \xi} S_{1,\xi}(u) \Big|_{\xi=0} = \mathbb{E} \left\{ \varphi_1^F(u | \mathcal{V}) \dot{S}(\mathcal{V}) \right\}$  where  $S_{1,\xi}(u) = \mathbb{E} \{ \tilde{\delta} d S_{1,\xi}(u | X) \}$ . Toward this end, we express

$$\begin{aligned}
\frac{\partial}{\partial \xi} S_{1,\xi}(u) \Big|_{\xi=0} &= \int \tilde{\delta} d S_{1,\xi}(u | X) f_\xi(\mathcal{V}) d\mathcal{V} \Big|_{\xi=0} \\
&= \int \tilde{\delta} d S_{1,\xi}(u | X) \dot{S}_\xi(V) f_\xi(\mathcal{V}) d\mathcal{V} \Big|_{\xi=0} \\
&\quad + \int \tilde{\delta} d \left\{ \frac{\partial}{\partial \xi} S_{1,\xi}(u | X) \right\} f_\xi(\mathcal{V}) d\mathcal{V} \Big|_{\xi=0} \\
&= \mathbb{E} \left\{ \tilde{\delta} d S_1(u | X) \dot{S}_\xi(X) \right\} + \mathbb{E} \left\{ \frac{\partial}{\partial \xi} S_{1,\xi}(u | X) \Big|_{\xi=0} \right\}. \tag{B1}
\end{aligned}$$

For the first term in (B1), we have

$$\begin{aligned}
&\mathbb{E} \left\{ \tilde{\delta} d S_1(u | X) \dot{S}(X) \right\} \\
&= \mathbb{E} \left[ \tilde{\delta} d \{ S_1(u | X) - S_1(u) \} \right] \\
&= \mathbb{E} \left[ \tilde{\delta} d \{ S_1(u | X) - S_1(u) \} \left\{ \dot{S}(X, A, T, \delta) + \tilde{\delta} \dot{S}(X) \right\} \right] \\
&= \mathbb{E} \left[ \tilde{\delta} d \{ S_1(u | X) - S_1(u) \} \dot{S}(\mathcal{V}) \right], \tag{B2}
\end{aligned}$$

and for the second term in (B1), we have

$$\begin{aligned}
\frac{\partial}{\partial \xi} S_{1,\xi}(u | X) \Big|_{\xi=0} &= \int I(T \geq u) \frac{\partial}{\partial \xi} f_\xi(u | X, \delta = 1, A = 1) du \Big|_{\xi=0} \\
&= \int I(T \geq u) \dot{S}_\xi(T | X, \delta = 1, A = 1) f_\xi(u | X, \delta = 1, A = 1) du \Big|_{\xi=0} \\
&= \int I(T \geq u) \dot{S}(T | X, \delta, A) \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} f(t | X) du \\
&= \mathbb{E} \left\{ \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} I(T \geq u) \dot{S}(T | X, \delta, A) \Big| X \right\}. \tag{B3}
\end{aligned}$$

By combining (B2) and (B3),

$$\begin{aligned}
\mathbb{E} \left\{ \frac{\partial}{\partial \xi} S_{1,\xi}(u | X) \Big|_{\xi=0} \right\} &= \mathbb{E} \left\{ \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} I(T \geq u) \dot{S}(T | X, \delta, A) \right\} \\
&= \mathbb{E} \left[ \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \{ I(T \geq u) - S_1(u | X) \} \dot{S}(T | X, \delta, A) \right] \\
&= \mathbb{E} \left[ \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \{ I(T \geq u) - S_1(u | X) \} \dot{S}(T, X, \delta, A) \right]
\end{aligned}$$

$$= \mathbb{E} \left[ \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \{I(T \geq u) - S_1(u | X)\} \dot{S}(\mathcal{V}) \right].$$

Therefore,

$$\frac{\partial}{\partial \xi} S_{1,\xi}(u) \Big|_{\xi=0} = \mathbb{E} \left( \left[ \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \{I(T \geq u) - S_1(u | X)\} + \tilde{\delta}d \{S_1(u | X) - S_1(u)\} \right] \dot{S}(\mathcal{V}) \right).$$

Let

$$\varphi_1^F(u | \mathcal{V}) = \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \{I(T \geq u) - S_1(u | X)\} + \tilde{\delta}d S_1(u | X) - S_1(u).$$

Since

$$\left\{ \tilde{\delta}d - \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \right\} S_1(u | X) \in H_3.$$

and

$$\frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} I(T \geq u) - S_1(u) \in H_4,$$

we have  $\varphi_1^F(u | \mathcal{V}) \in H$ , thus  $\varphi_1^F(u | \mathcal{V})$  is the EIF for  $S_1(u)$ .

Now, in the presence of censoring, we observe data set  $\mathcal{O} = (X, A, U, \Delta, \delta, \tilde{\delta})$  instead of  $\mathcal{V}$ .

Following Robins et al. (1995) and Tsiatis (2006), the EIF for the monotone coarsened data is

$$\begin{aligned} & \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{\Delta}{K_1^C(U, X)} I(U \geq u) - S_1(u) \\ & - \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \left\{ S_1(u | X) - \tilde{\delta}d \right\} S_1(u | X) \\ & + \int \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{dM_1^C(r, X)}{K_1^C(r, X)} g(u, r, X) \end{aligned}$$

where  $K_1^C(r, X) = p(C \geq r | X, A = 1, \delta = 1)$  and  $dM_1^C(r, X) = dN^C(r) - \lambda_1^C(r, X)Y(r)$ ,  $N^C(r) = I(U \leq r, \Delta = 1)$  and  $Y(r) = I(U \geq r)$ . According to Theorem 10.4 from Tsiatis (2006), the optimal  $g(u, r, X)$  is

$$g(u, r, X) = \mathbb{E} \{I(T \geq u | X, A = 1, \delta = 1, T \geq r)\}.$$

Thus,

$$\int \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{dM_1^C(r, X)}{K_1^C(r, X)} g(u, r, X)$$



$$\begin{aligned}
&= \int_0^\infty \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{dM_1^C(r, X)}{K_1^C(r, X)} \left\{ I(u > r) \frac{S_1(u | X)}{S_1(r | X)} + I(r \geq u) \cdot 1 \right\} \\
&= \int_0^u \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{dM_1^C(r, X)}{K_1^C(r, X)} \frac{S_1(u | X)}{S_1(r | X)} + \int_u^\infty \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{dM_1^C(r, X)}{K_1^C(r, X)}. \tag{B4}
\end{aligned}$$

For the second term in (B4), we can express as

$$\begin{aligned}
\text{(B4)} &= \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \left\{ \int_u^\infty \frac{dN^C(r)}{K_1^C(r, X)} - \int_u^\infty \frac{\lambda_1(r, X)Y(r)}{K_1^C(r, X)} \right\} \\
&= \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} Y(u) \left\{ \frac{1 - \Delta}{K_1^C(U, X)} - \int_u^U \frac{\lambda_1(r, X)}{K_1^C(r, X)} \right\} \\
&= \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} Y(u) \left[ \frac{1 - \Delta}{K_1^C(U, X)} - \left\{ \frac{1}{K_1^C(U, X)} - \frac{1}{K_1^C(u, X)} \right\} \right] \\
&= \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} Y(u) \left\{ \frac{1}{K_1^C(u, X)} - \frac{\Delta}{K_1^C(U, X)} \right\}. \tag{B5}
\end{aligned}$$

Plugging (B5) to (B4), the EIF for  $S_1(u)$  under  $\Theta$  is

$$\begin{aligned}
&\frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{\Delta}{K_1^C(U, X)} I(U \geq u) - S_1(u) \\
&- \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \left\{ S_1(u | X) - \tilde{\delta}d \right\} S_1(u | X) \\
&+ \int_0^u \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{dM_1^C(r, X)}{K_1^C(r, X)} \frac{S_1(u | X)}{S_1(r | X)} \\
&- \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} Y(u) \left\{ \frac{1}{K_1^C(u, X)} - \frac{\Delta}{K_1^C(U, X)} \right\} \\
&= \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{I(U \geq u)}{K_1^C(u, X)} - S_1(u) \\
&- \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \left\{ S_1(u | X) - \tilde{\delta}d \right\} S_1(u | X) \\
&+ \int_0^u \frac{\delta}{\pi_\delta(X)} \frac{A}{\pi_A(X)} \frac{dM_1^C(r, X)}{K_1^C(r, X)} \frac{S_1(u | X)}{S_1(r | X)}.
\end{aligned}$$

The EIF for  $S_0(t)$  can be obtained by analogy.

## B.2 Proof of Corollary 1

For both ACW1 and ACW2 estimators, by the definition of the EIF,

$$\sqrt{N} \left\{ \widehat{S}_a^{\text{ACW}}(t) - S_a(t) \right\} = \frac{1}{\sqrt{N}} \sum_{i=1}^N \varphi_a^{\text{eff}}(t; \Theta_i) + o_p(1), \text{ for } a \in \{0, 1\}.$$

Thus, under asymptotic linear characterization of the ATE estimator  $\widehat{\theta}_\tau^{\text{ACW}} = \Psi_\tau \left( \widehat{S}_1^{\text{ACW}}(t), \widehat{S}_0^{\text{ACW}}(t) \right)$ ,

$$\begin{aligned} \sqrt{N}(\widehat{\theta}_\tau^{\text{ACW}} - \theta_\tau) &= \int_0^\tau \phi_1(t) \sqrt{N} \left\{ \widehat{S}_1^{\text{ACW}}(t) - S_1(t) \right\} dt + \int_0^\tau \phi_0(t) \sqrt{N} \left\{ \widehat{S}_0^{\text{ACW}}(t) - S_0(t) \right\} dt + o_p(1) \\ &= \int_0^\tau \phi_1(t) \frac{1}{\sqrt{N}} \sum_{i=1}^N \varphi_1^{\text{eff}}(t; \mathcal{O}_i) dt + \int_0^\tau \phi_0(t) \frac{1}{\sqrt{N}} \sum_{i=1}^N \varphi_0^{\text{eff}}(t; \mathcal{O}_i) dt + o_p(1) \\ &= \frac{1}{\sqrt{N}} \sum_{i=1}^N \left\{ \int_0^\tau \phi_1(t) \varphi_1^{\text{eff}}(t; \mathcal{O}_i) dt + \int_0^\tau \phi_0(t) \varphi_0^{\text{eff}}(t; \mathcal{O}_i) dt \right\} + o_p(1). \end{aligned}$$

Thus, the EIF for  $\theta_\tau$  is

$$\varphi_{\theta_\tau}^{\text{eff}}(\mathcal{O}) = \int_0^\tau \phi_1(t) \varphi_1^{\text{eff}}(t; \mathcal{O}) dt + \int_0^\tau \phi_0(t) \varphi_0^{\text{eff}}(t; \mathcal{O}) dt.$$

### B.3 Proof of Theorem 2

Standard regularity conditions for the consistency of survival outcome regression parameters and treatment propensity score model (e.g., Lin and Wei, 1989; Zhang and Schaubel, 2012b), as well as suitable regularity conditions for the M-estimation theory (e.g., Van der Vaart, 2000) are assumed throughout this proof. The former includes almost sure boundedness of  $X$  and finite cumulative baseline hazard function for survival and censoring, and the latter includes smoothness and identifiability of working models and applicability of dominated convergence theorem.

Under Assumptions 1–3, we consider three cases; (i) survival outcome regression model (O) in (3) is correctly specified, (ii) the weighting models, i.e., the sampling score model (S) in (7), the treatment propensity score model (A) in (8), and the censoring model (C) in (9), are correctly specified, (iii) all working models in (3) and (7)–(9) are correctly specified. Assume that  $\widehat{\zeta} = (\widehat{\eta}, \widehat{\rho}, \widehat{\beta}_1, \widehat{\beta}_0, \widehat{\gamma}_1, \widehat{\gamma}_0)$  converges to some  $\zeta^* = (\eta^*, \rho^*, \beta_1^*, \beta_0^*, \gamma_1^*, \gamma_0^*)$ , not necessary true. Then,  $\widehat{\pi}_\delta(X) = \pi_\delta(X; \widehat{\eta}) = \exp\{\widehat{\eta}^T \mathbf{g}(X)\}$  converges to  $\pi_\delta^*(X)$ ,  $\widehat{\pi}_A(X) = \pi_A(X; \widehat{\rho}) = [1 + \exp\{-\widehat{\rho}^T \mathbf{g}(X)\}]^{-1}$  converges to  $\pi_A^*(X)$ ,  $\widehat{\Lambda}_a(t) = \widehat{\Lambda}_a(t; \widehat{\beta}_a)$  converges to  $\Lambda_a^*(t)$ , and  $\widehat{\Lambda}_a^C(t) = \widehat{\Lambda}_a^C(t; \widehat{\gamma}_a)$  converges to  $\Lambda_a^{*C}(t)$ , for  $a \in \{0, 1\}$ . The following proof is similar to the one in Zhang and Schaubel (2012b) and Zhang et al. (2019).

## Double Robustness

We first demonstrate the double robustness property of  $\widehat{S}_1^{\text{ACW1}}(t)$ . It is straightforward to show double robustness of  $\widehat{S}_0^{\text{ACW1}}(t)$  and  $\widehat{\theta}^{\text{ACW1}}$  by analogy. For the simplicity, we only consider the simple random sampling in the observational study, but it can be easily extended to the general setting with known design weights. Under mild regularity conditions,  $\widehat{S}_1^{\text{ACW1}}(t) \xrightarrow{p} \mathfrak{S}_1(t; \zeta^*)$  where

$$\mathfrak{S}_1(t; \zeta^*) = \mathbb{E} \left\{ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} \frac{Y(t)}{e^{-\Lambda_a^*(t)}} \right\} \quad (\text{B6})$$

$$- \mathbb{E} \left[ \frac{\delta}{\pi_\delta^*(X)} \left\{ \frac{A - \pi_A^*(X)}{\pi_A^*(X)} \right\} e^{-\Lambda_1^*(t)} \right] \quad (\text{B7})$$

$$- \mathbb{E} \left[ \left\{ \frac{\delta}{\pi_\delta^*(X)} - \widetilde{\delta}d \right\} e^{-\Lambda_1^*(t)} \right] \quad (\text{B8})$$

$$+ \mathbb{E} \left\{ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} \int_0^t \frac{dM_1^{*C}(u)}{e^{-\Lambda_1^{*C}(t)}} \frac{e^{-\Lambda_1^*(t)}}{e^{-\Lambda_1^*(u)}} \right\}. \quad (\text{B9})$$

First, consider the condition (i) that the model for O is correct. Using the notation  $\kappa(t)$  from Zhang and Schaubel (2012b), we can express  $Y(t) = I(T \geq t)\kappa(t)$  where  $\kappa(t) = I(C \geq T \text{ or } C \geq t)$ . Following Tsiatis (2006, Chapter 9.3 and Lemma 10.4), we can write

$$\frac{\kappa(t)}{e^{-\Lambda_1^{*C}(t)}} = 1 - \int_0^t \frac{dM_1^{*C}(u)}{e^{-\Lambda_1^{*C}(t)}}.$$

Then we have

$$\begin{aligned} (\text{B6}) &= \mathbb{E} \left\{ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} \frac{I(T \geq t)\kappa(t)}{e^{-\Lambda_1^{*C}(t)}} \right\} \\ &= \mathbb{E} \left\{ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} I(T \geq t) - \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} \int_0^t \frac{dM_1^{*C}(u)}{e^{-\Lambda_1^{*C}(t)}} I(T \geq t) \right\} \end{aligned} \quad (\text{B10})$$

$$(\text{B7}) + (\text{B8}) = - \mathbb{E} \left\{ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} e^{-\Lambda_1^*(t)} \right\} \quad (\text{B11})$$

$$+ \mathbb{E} \left\{ \widetilde{\delta}d e^{-\Lambda_1^*(t)} \right\}. \quad (\text{B12})$$

Combining (B9) with (B10)–(B12), we have

$$\mathbb{E} \left\{ \widetilde{\delta}d e^{-\Lambda_1^*(t)} \right\} \quad (\text{B13})$$

$$+ \mathbb{E} \left[ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} \{ I(T \geq t) - e^{-\Lambda_1^*(t)} \} \right] \quad (\text{B14})$$

$$+ \mathbb{E} \left[ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} \int_0^t \frac{dN_1^C(u)}{e^{-\Lambda_1^{*C}(t)}} \left\{ I(T \geq t) - \frac{e^{-\Lambda_1^*(t)}}{e^{-\Lambda_1^*(u)}} \right\} \right] \quad (\text{B15})$$

$$- \mathbb{E} \left[ \frac{\delta}{\pi_\delta^*(X)} \frac{A}{\pi_A^*(X)} \int_0^t \frac{Y(u) d\Lambda_1^{*C}(u)}{e^{-\Lambda_1^{*C}(t)}} \left\{ I(T \geq t) - \frac{e^{-\Lambda_1^*(t)}}{e^{-\Lambda_1^*(u)}} \right\} \right]. \quad (\text{B16})$$

Since  $e^{-\Lambda_1^*(t)} = p(T \geq t \mid X, A = 1, \delta = 1)$ , (B13) equals to  $S_1(t)$  and (B14) is 0 by iterated expectation conditioning on  $(X, A = 1, \delta = 1)$ . Also (B15) and (B16) are 0 by iterated expectations conditioning on  $(X, A = 1, \delta = 1, C = u, T \geq u)$  and  $(X, A = 1, \delta = 1, C \geq u, T \geq u)$ , respectively.

Now, consider the condition (ii) that the models for S, A, and C are correct. As  $\pi_\delta^*(X) = p(\delta = 1 \mid X)$ ,  $\pi_A^*(X) = p(A = 1 \mid X, \delta = 1)$ , and  $e^{-\Lambda_1^{*C}(t)} = p(C \geq t \mid X, A = 1, \delta = 1)$ ,

$$\begin{aligned} (\text{B6}) &= \mathbb{E} \left[ \frac{\delta}{\pi_\delta^*(X)} \mathbb{E} \left\{ \frac{A}{\pi_A^*(X)} \frac{I(T \geq t) I(C \geq t)}{e^{-\Lambda_1^{*C}(t)}} \middle| X, \delta = 1 \right\} \right] \\ &= \mathbb{E} \left\{ \frac{\delta}{\pi_\delta^*(X)} \frac{\pi_A^*(X) P(T \geq t \mid X, A = 1, \delta = 1) P(C \geq t \mid X, A = 1, \delta = 1)}{\pi_A^*(X) e^{-\Lambda_1^{*C}(t)}} \right\} \\ &= \mathbb{E} \left\{ \tilde{\delta} d P(T \geq t \mid X, A = 1, \delta = 1) \right\} \\ &= S_1(t) \end{aligned}$$

$$(\text{B7}) + (\text{B8}) = \mathbb{E} \left[ e^{-\Lambda_1^*(t)} \left\{ \tilde{\delta} d - \frac{\delta}{\pi_\delta^*(X)} \frac{\pi_A^*(X)}{\pi_A^*(X)} \right\} \right] = 0$$

$$(\text{B9}) = \mathbb{E} \left[ \frac{\delta}{\pi_\delta^*(X)} \frac{\pi_A^*(X)}{\pi_A^*(X)} \mathbb{E} \left\{ \int_0^t \frac{dM_1^{*C}(u)}{e^{-\Lambda_1^{*C}(t)}} \frac{e^{-\Lambda_1^*(t)}}{e^{-\Lambda_1^*(u)}} \middle| X, A = 1, \delta = 1 \right\} \right] = 0.$$

Thus,  $\widehat{S}_0^{\text{ACW1}}(t)$  has the double robustness property. By analogy, it is straightforward to show that  $\widehat{S}_0^{\text{ACW1}}(t)$  converges to  $S_0(t; \zeta^*)$  which equals to  $S_0(t)$  if either working model for O or weighting models S, A, and C are correct. Consequently,  $\widehat{\theta}_\tau^{\text{ACW1}}$  converges to  $\vartheta_\tau(\zeta^*)$ , where

$$\vartheta_\tau(\zeta^*) = \int_0^\tau \phi_1(t) \mathcal{S}_1(t; \zeta^*) dt + \int_0^\tau \phi_0(t) \mathcal{S}_0(t; \zeta^*) dt.$$

Then,  $\vartheta_\tau(\zeta^*)$  equals to  $\theta_\tau$  with the same double robustness properties.

For the ACW2 estimator, we can show that the numerator  $-d\widehat{S}_1^{\text{ACW1}}(u)$  converges in probability to  $-dS_1(u)$ , thus  $\widehat{S}_1^{\text{ACW2}}(t) \xrightarrow{p} S_1(t)$ . Similarly, one can easily obtain  $\widehat{S}_0^{\text{ACW2}}(t) \xrightarrow{p} S_0(t)$  and  $\widehat{\theta}_\tau^{\text{ACW2}} \xrightarrow{p} \theta_\tau$ .

## Asymptotic Normality

Following empirical process literature, define  $\mathbb{P}_0$  as the true measure,  $\mathbb{P}_N$  as the empirical measure, and define  $\mathbb{G}_N = \sqrt{N}(\mathbb{P}_N - \mathbb{P}_0)$  for the empirical processes. Following the technique used in Zhang et al. (2019), we assume that  $\zeta$  and  $\zeta^*$  takes values in a suitable Banach space with

$$\begin{aligned}\sqrt{N}(\widehat{\eta} - \eta^*) &= \mathbb{G}_N \varphi_\eta(\mathcal{O}) + o_p(1) \\ \sqrt{N}(\widehat{\rho} - \rho^*) &= \mathbb{G}_N \varphi_\rho(\mathcal{O}) + o_p(1) \\ \sqrt{N}(\widehat{\beta}_a - \beta_a^*) &= \mathbb{G}_N \varphi_{\beta_a}(\mathcal{O}) + o_p(1) \\ \sqrt{N}(\widehat{\gamma}_a - \gamma_a^*) &= \mathbb{G}_N \varphi_{\gamma_a}(\mathcal{O}) + o_p(1),\end{aligned}\tag{B17}$$

for  $a \in \{0, 1\}$ . Assuming that  $\vartheta_\tau(\zeta^*)$  belongs to Donsker classes (Van Der Vaart et al., 1996; Kennedy, 2016), and under assumed regularity conditions,  $\mathbb{P}_N \vartheta_\tau(\widehat{\zeta}) = \widehat{\theta}_\tau^{\text{ACW1}}$  and  $\mathbb{P} \vartheta_\tau(\zeta^*) = \theta_\tau$ . Then,

$$\begin{aligned}\sqrt{N} \left\{ \widehat{\theta}_\tau^{\text{ACW1}} - \theta_\tau \right\} &= \sqrt{N} \left\{ \mathbb{P}_N \vartheta_\tau(\widehat{\zeta}) - \mathbb{P} \vartheta_\tau(\zeta^*) \right\} \\ &= \mathbb{G}_N \vartheta_\tau(\widehat{\zeta}) + \sqrt{N} \mathbb{P} \left\{ \vartheta_\tau(\widehat{\zeta}) - \vartheta_\tau(\zeta^*) \right\} \\ &= \mathbb{G}_N \vartheta_\tau(\zeta^*) + \sqrt{N} \mathbb{P} \left\{ \vartheta_\tau(\widehat{\zeta}) - \vartheta_\tau(\zeta^*) \right\} + o_p(1).\end{aligned}$$

As  $\vartheta$  is differentiable at  $\zeta^*$ , we have the derivative

$$D^{\text{ACW}} = (D_\eta^{\text{ACW}}, D_\rho^{\text{ACW}}, D_{\beta_1}^{\text{ACW}}, D_{\beta_0}^{\text{ACW}}, D_{\gamma_1}^{\text{ACW}}, D_{\gamma_0}^{\text{ACW}}) = \int_0^\tau \{ \phi_1(t) D\mathcal{S}_1 + \phi_0(t) D\mathcal{S}_0 \} dt.$$

This implies that

$$\begin{aligned}& \sqrt{N} \mathbb{P} \left\{ \vartheta_\tau(\widehat{\zeta}) - \vartheta_\tau(\zeta^*) \right\} \\ &= D^{\text{ACW}} \sqrt{N}(\widehat{\eta} - \eta^*, \widehat{\rho} - \rho^*, \widehat{\beta}_1 - \beta_1^*, \widehat{\beta}_0 - \beta_0^*, \widehat{\gamma}_1 - \gamma_1^*, \widehat{\gamma}_0 - \gamma_0^*) + o_p(1) \\ &= \mathbb{G}_N (D_\eta^{\text{ACW}} \varphi_\eta + D_\rho^{\text{ACW}} \varphi_\rho + D_{\beta_1}^{\text{ACW}} \varphi_{\beta_1} + D_{\beta_0}^{\text{ACW}} \varphi_{\beta_0} + D_{\gamma_1}^{\text{ACW}} \varphi_{\gamma_1} + D_{\gamma_0}^{\text{ACW}} \varphi_{\gamma_0}) + o_p(1).\end{aligned}$$

Therefore,

$$\sqrt{N} \left\{ \widehat{\theta}_\tau^{\text{ACW1}} - \theta_\tau \right\} = \mathbb{G}_N \left\{ \vartheta_\tau(\zeta^*) + D_\eta^{\text{ACW}} \varphi_\eta + D_\rho^{\text{ACW}} \varphi_\rho + D_{\beta_1}^{\text{ACW}} \varphi_{\beta_1} + D_{\beta_0}^{\text{ACW}} \varphi_{\beta_0} + D_{\gamma_1}^{\text{ACW}} \varphi_{\gamma_1} + D_{\gamma_0}^{\text{ACW}} \varphi_{\gamma_0} \right\}$$

$$+ o_p(1).$$

The similar technique can be used to prove the asymptotic normality of the ACW2 estimator using the Delta method and the M-estimation theory.

### Local Efficiency

Define the asymptotic variance of the ACW1 estimator as  $\mathbb{E}(\varsigma_1^2)$ , where

$$\varsigma_1 = \vartheta_\tau(\zeta^*) + D_\eta^{\text{ACW}} \varphi_\eta + D_\rho^{\text{ACW}} \varphi_\rho + D_{\beta_1}^{\text{ACW}} \varphi_{\beta_1} + D_{\beta_0}^{\text{ACW}} \varphi_{\beta_0} + D_{\gamma_1}^{\text{ACW}} \varphi_{\gamma_1} + D_{\gamma_0}^{\text{ACW}} \varphi_{\gamma_0}.$$

When the model for O is correct, then  $D_{\beta_1}^{\text{ACW}} = 0$  and  $D_{\beta_0}^{\text{ACW}} = 0$ . When the weighting models S, A, and C are correct then  $D_\eta^{\text{ACW}}, D_\rho^{\text{ACW}}, D_{\gamma_1}^{\text{ACW}}, D_{\gamma_0}^{\text{ACW}}$  are all zero. Thus, when all four working models are correct, then

$$\sqrt{N} \left\{ \widehat{\theta}_\tau^{\text{ACW1}} - \theta_\tau \right\} = \mathbb{G}_N \vartheta_\tau(\zeta^*) + o_p(1) = \mathbb{G}_N \varphi_{\theta_\tau}^{\text{eff}}(\mathcal{O}) + o_p(1),$$

i.e.,  $\varsigma_1 = \varphi_{\theta_\tau}^{\text{eff}}(\mathcal{O})$ , implying that the ACW1 estimator is the locally efficient estimator. The efficiency of the ACW2 estimator can be proved using the similar technique and the small order difference between the ACW1 and the ACW2 estimator.